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Arrhythmogenic right venticular dysplasia/cardiomyopathy (ARVD/C) is an inherited
cardiomyopathy with a very low penetrance aﬀecting the right ventricle (RV) and presenting
palpitation and syncope due to ventricular tachycardia (VT) originating from RV. The VT can
degenerate into ventricular ﬁbrillation and sudden cardiac death. The genetic background of
ARVD/C has recently been found to be heterogeneous, mainly resulting from cell adhesion
abnormalities due to mutations in ﬁve diﬀerent genes encoding members of the desmosome
complex. In Asian countries, however, the genetic aspect of the disease has not been fully
studied, although the clinical features of Asian ARVD/C patients are diﬀerent from those in
Western countries in the penetrance of phenotypes, relation to Brugada syndrome and link to
RV outﬂow tract ventricular tachycardia. It is of urgent need to have a registry of Asian
ARVD/C patients and to conduct a more detailed genetic survey on the candidate genes,
including desomosomal ones.
(J Arrhythmia 2008; 24: 195–199)
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Introduction
Arrhythmogenic right venticular dysplasia/cardi-
omyopathy (or ARVD/C) is an inherited cardiomy-
opathy with a very low penetrance aﬀecting the right
ventricle (RV) and presenting palpitation and syn-
cope due to ventricular tachycardia (VT) originating
from RV.1–3) The VT can degenerate into ventricular
ﬁbrillation and sudden cardiac death (SCD). The
disease is three times more prevalent in men than in
women. An Italian study4) gives an estimated
prevalence for ARVD/C ranging from 1 in 2,000
to 1 in 5,000. In contrast, it has been reported to be
only 1 in 160,000 in Japan.5) Although detailed
epidemiology and prevalence of ARVD/C remains
unknown in Asian countries, there is a deﬁnite ethnic
diﬀerence in the occurrence of the disease. Sudden
death can be the ﬁrst clinical manifestation of the
disease in more than 50% of patients with ARVC.6)
This indicates that fatal ventricular arrhythmias can
cause SCD even in the concealed stage with subtle
RV structural change.7)
Although fatty and/or ﬁbro-fatty replacement of
the RV myocardium is the pathological hallmark of
the disease,8) RV biopsy is of limited use for patients
Address for correspondence: Minoru Horie MD, Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical
Sciences, Seta Tsukinowa, Otsu, Shiga, 520-2192, Japan. Fax: +81-77-543-5839 Phone: +81-77-548-2213 E-mail: horie@belle.shiga-
med.ac.jp
195
Horie M Genetic background of ARVD/C
Review Article
in the stage with minimally involvement and is too
invasive as a technique for diagnosis. In addition,
some of the other criteria suggested by task forces8–10)
cannot be applied to patients in earlier stages of the
disease. Therefore, another approach is needed for its
diagnosis. More recently, vigorous studies inWestern
countries unveiled the molecular and genetic back-
grounds of the disease: 11 chromosomal loci and 7
responsible genes have been reported (Table 1),
oﬀering another diagnostic method.
Desmosomal genes and ARVD/C
The studies screening the genetic background
have been conducted because familial cases ac-
counted for 30% to 50% in Europe,8,11) showing an
autosomal dominant trait with incomplete pene-
trance. As listed in Table 1, ARVD/C is now known
to be very heterogenous, mainly resulting from cell
adhesion abnormalities since ﬁve identiﬁed respon-
sible genes are all coding members of the desmo-
some complex (Figure). It is a cell adhesion
apparatus which binds neighboring cells tightly and
consists of at least 5 associated proteins. The
discovery of desmosomal gene mutations as a
genetic variant responsible for ARVD/C started
from the clinical description of Naxos disease
(Table 1) in 1986 by Greek physicians, Protonotarios
and colleagues.12) They reported that Naxos disease
is inherited in an autosomal recessive manner,
speciﬁc to the Naxos island of Aegean Sea and
characterized by (1) ARVD/C, (2) palmoplantar
keratoderma and (3) wooly hair. By a means of
linkage analysis in typical families, a mutation in the
gene encoding plakoglobin (a member of desmo-
some complex proteins: JUP) was identiﬁed to cause
the disease 14 years after it was ﬁrst described.13)
Thereafter many researchers began to speculate that
mutations in gene members coding the desmosomal
complex might be associated with the disease. In
other words, the discovery of plakoglobin triggered
the hypothesis that the disorder is linked to abnor-
malities in cell adhesion molecules, i.e., desmosomal
proteins. Within several years, mutations in 4 other
desmosomal genes, desmoplakin (DSP: ARVC8),
plakophillin (PKP2: ARVC9), desmoglein (DSG2:
ARVC10) and desmocollin (DSC2: ARVC11), have
been reported to be responsible for ARVD/C
(Table 1 & Figure).
Genetic background of Asian ARVD/C patients
remains unclear
In Western countries, PKP2 mutations have been
shown to be most prevalent in patients. Various
types of PKP2 mutations were identiﬁed in 27% of
120,14) 43% of 5815) and in 43% of 56 patients.16) In
contrast, the genetic background and precise distri-
bution of desmosomal gene mutations are unknown
in Asian countries. More recently, we have started to
collect genomic DNA from the registry of Japanese
ARVD/C patients and published case reports on
novel PKP2 mutations.17,18) Our results on a limited
number of ARVD/C probands revealed that PKP2
mutations are also common in Japan (6 of 17
probands, 35%).19)
As for a reason why Western researchers could so
rapidly conduct detailed genetic screening on their
ARVD/C patients or why we were delayed, it was of
clinical importance that they had already full sets
of genomic DNA collections, because was well
understood that ARVD/C is a hereditary disease.
Table 1 Genetic classiﬁcation of ARVD/C
Type Gene Coding Protein Locus Mode of inheritance
ARVC 1 TGF-3 TGF-3 14q24 AD
ARVC 2 RyR2 Ryanodine receptor 1q42-q43 AD
ARVC 3 ? ? 14q12-q22 AD
ARVC 4 ? ? 2q32.1-q32.3 AD
ARVC 5 TMEM43 Transmembran protein 3p23 AD
ARVC 6 ? ? 10p12-p14 AD
ARVC 7 ? ? 10q22.3 AD
ARVC 8 DSP Desmoplakin 6p24 AD/AR
ARVC 9 PKP2 Plakophilin 12p11 AD/AR
ARVC10 DSG2 Desmoglein 18q12.1-q12.2 AD
ARVC11 DSC2 Desmocollin 18q12.1 AD
Naxos JUP Plakoglobin 17q21 AR
AD: autosomal dominant, AR: autosomal recessive
ARVD/C is here denoted as ARVC.
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Our clinical impression on ARVD/C, however,
somewhat diﬀers from theirs: the occurrence of the
disease is sporadic and familial cases are rather rare.
Regarding a case of young boy in whom we could
identify a novel PKP2 mutation, Q378X, extensive
genetic tests in his family members revealed that his
parents were free of mutation, indicating that the
mutation was de novo and this was really a sporadic
case.18) However, the precise prevalence of de novo
cases remains unknown because of lack of data
available for genomic DNA of patients.
Based on autopsy data of 38 Korean patients with
SCD, Cho and his colleagues20) demonstrated that
ARVD/C was the most common cause of SCD
(42%) and most of victims were found dead in bed or
during ordinary daily activity. These properties
diﬀer from those reported by European researchers.
Their patients’ SCD is reportedly associated with
strenuous exercise. Therefore, it is now time to start
a global registry of Asian ARVD/C patients and to
conduct a more extensive genetic survey on the
candidate genes, including desmosomal ones. The
genetic proﬁle of our ARVD/C cases may reﬂect
ethnic diﬀerences from those reported in Western
countries in terms of responsible genes and their
penetrance.
Other unresolved issues in the ARVD/C study
One of the major remaining questions is why the
disease ﬁrst aﬀects the RV. As we now know that
ARVD/C is very heterogeneous in terms of genetic
causes, there may be gene-speciﬁc variations in
phenotype. Some types may develop fatal arrhyth-
mia before structural changes in RV and others may
not. Indeed, PKP2 mutations appeared to be more
arrhythmogenic from an earlier stage of the disease.
These diﬀerences in clinical features may partially
result from PKP2 linkage with other key molecules
for cell-to-cell connection.21,22)
In order to diagnose possible ARVD/C cases, task
force or modiﬁed diagnostic criteria have been
widely used (Table 2).8–10) The diagnosis of ARVD/
C can be fulﬁlled by the presence of 2 major criteria,
or 1 major plus 2 minor criteria, or 4 minor criteria
from diﬀerent groups. For example if your patient has
a conﬁrmed family history and severe RV dilatation
with reduced RV ejection fraction, he is most
probably aﬀected with ARVD/C. However, the
current criteria are not applicable to patients with
earlier stages of disease who have no family history.
Nevertheless, fatal arrhythmias can occur from the
very beginning of disease development. Therefore,
the genetic testing focusing on desmosomal genes
oﬀers a strong diagnostic tool, particularly for
patients in an early stage of the disease and family
members with genetically conﬁrmed ARVD/C pro-
bands.
As another unanswered issue, some ARVD/C
cases overlap clinical features with nocturnal sudden
death (or Brugada syndrome) and VT originating
from the RV outﬂow.23–29) The former syndrome
may not only be primarily electrical but may involve
structural disease, especially in the RV outﬂow area.
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(Naxos disease) 
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Filaments
Intermediate
Figure A scheme showing several mole-
cules contributing to form the desmosomal
complex.
Mutations in gene respective protein causes
diﬀerent type of ARVD/C as indicated in
parentheses.
EC: extracellular space, IC: intracellular space
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Back to late 80s, prior to the report of Brugada et
al.,23) Martini et al.24) described the ECG ﬁndings of
right bundle branch block and ST-segment elevation
in survivors from cardiac sudden death and observed
morphological wall motion abnormalities of the RV
in ﬁve of six patients, RV enlargement, signiﬁcant
ﬁbrous adipose replacement in the free wall, and
remarkable ﬁbrosis of the bifurcating bundle and
proximal bundle branches in one autopsy case. Years
later, using non-invasive examinations, Corrado et
al.,25) Takagi et al.26) and Papavassiliu et al.27)
independently demonstrated subtle RV structural
changes in patients with Brugada syndrome. More
recently, Coronel et al.28) reported a case of Brugada
syndrome that underwent cardiac transplantation,
and detailed analyses on the patient’s explanted heart
revealed the RV hypertrophy and ﬁbrosis with
epicardial fatty inﬁltration, causing the conduction
delay in the RV outﬂow.
Regarding the relation between ARVD/C and RV
outﬂow-origin VT, we identiﬁed a missense muta-
tion of desmoplakin (DSP) in an 18-year-old female
who complained of recurrent presyncope due to non-
sustained VT from the RV outﬂow tract but did not
satisfy the criteria (no family history, no morpho-
logical abnormality). Catheter ablation was partially
successful to suppress her VT, and we are carefully
following the patient to see whether she develops
typical phenotypes of ARVD/C under the concept
that RV outﬂow tract VT can be a very early stage of
forme fruste ARVD/C.29)
In conclusion, both clinical and genetic aspects of
ARVD/C are not yet fully studied in Asians.
Although the disease is uncommon, it is feasible to
ﬁnd a breakthrough for the etiology of other over-
lapping diseases such as RV outﬂow tract VT,
Brugada syndrome or even common VT. Finally, let
us make a remark again that recent swift progress on
ARVD/C study was mostly triggered by the discov-
ery of genes responsible for the Naxos disease. It
reminds us of Dr. William Harvey’s famous epi-
gram: the study of uncommon illness often allows us
Table 2 Criteria for Diagnosis of ARVD/C
1. Family history
Major: Familial disease conﬁrmed at necropsy or surgery.
Minor: Family history of premature sudden death (<35 years of age) due to suspected
ARVD/C.
Family history (clinical diagnosis based on present criteria).
2. ECG depolarization/conduction abnormalities
Major: Epsilon waves or localized prolongation (>110ms) of QRS complex in right
precordial leads (V1–V3).
Minor: Late potentials on signal-averaged ECG.
3. ECG repolarization abnormalities
Minor: Inverted T waves in right precordial leads (V2 and V3) in people >12 years of
age and in absence of right bundle branch block.
4. Arrhythmias
Minor: Sustained or nonsustained left bundle branch block-type ventricular tachycardia
documented on ECG or Holter monitoring or during exercise testing.
Frequent ventricular extrasystoles (>1000=24 h on Holter monitoring).
5. Global or regional dysfunction and structural alterations
Major: Severe dilatation and reduction of RV ejection fraction with no or mild LV
involvement.
Localized RV aneurysms (akinetic or dyskinetic areas with diastolic bulgings).
Severe segmental dilatation of RV.
Minor: Mild global RV dilatation or ejection fraction reduction with normal LV.
Mild segmental dilatation of RV.
Regional RV hypokinesia.
6. Tissue characteristics of walls
Major: Fibrofatty replacement of myocardium on endomyocardial biopsy.
Detected by echocardiography, angiography, magnetic resonance imaging, or radionuclide
scintigraphy. (ref. #9)
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to better understand the mechanisms of common
disease. It is now time to start an extensive registry
of Asian ARVD/C patients.
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